Caldwell, an executive search firm, named John Staines as partner and leader of its Global HR Practice. Staines brings over 35 years of experience in senior HR leadership and executive search, having held multiple chief HR officer roles across various industries. His appointment strengthens Caldwell's ability to advise clients on recruiting top HR executives and building leadership teams that drive growth and transformation. This move follows recent expansions in Caldwell's global HR team, aiming to better serve clients worldwide.
John Staines' appointment to lead Caldwell's Global HR Practice is noted alongside Pluang's Industrials sector market data. For readers following Industrials, here is Pluang's market snapshot as of Oct 13, 2026 20:51 WIB: of 113 priced US Industrials stocks, 38 rose and 75 fell. Notable movers include LUNR at USD 12.34 with a -4.04% change and 100% buy order activity, DAC at USD 162.91 down 3.25% with 100% buy orders, and RKLB at USD 63.68 down 3.09% with 58% buy orders and 42% sell orders.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
